LKFT Stock: Price, Earnings History and SEC Filings
Lakefront Biotherapeutics NV (LKFT) last traded at $32.28, down 0.15% on the latest session and up 8.9% over the past month. In its most recent reported quarter (Mar 2026) earnings per share were $0.25 against an analyst estimate of $-1.27, a beat of 119.7%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
LKFT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Mar 2026 | May 6, 2026 | $0.25 | $-1.27 | +119.69% |
LKFT beat the analyst EPS estimate in 1 of its last 1 reported quarters. Source: Nasdaq.
Latest SEC filings for LKFT
Insider filing activity
LKFT insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
LKFT news
- Lakefront Biotherapeutics - Sponsored ADR (LKFT) Upgraded to Buy: What Does It Mean for the Stock?Oct 21, 2026 · finance.yahoo.com
- Lakefront Biotherapeutics (ENXTAM:LKFT) Stock Looks Undervalued Despite A 40% Five Year FallOct 21, 2026 · finance.yahoo.com
- Acquisition of Own SharesOct 20, 2026 · finance.yahoo.com
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV (LKFT) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in Belgium.